Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: ValuEngine, Inc.
|
$127.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Kforce Inc. Enters Into A Stock Purchase Agreement To Sell Its Clinical Research Business
Kforce Inc. announced that it has entered into a Stock Purchase Agreement (Agreement) with inVentiv Health, Inc. (inVentiv) dated March 17, 2012, to sell all of the issued and outstanding shares of capital stock of Kforce Clinical Research, Inc. (KCR) for an aggregate purchase price of $50 million in cash. Kforce expects the transaction to close at the end of March, subject to customary closing conditions. Robert W. Baird and Company is acting as advisor to Kforce Inc. on this transaction.
Latest Key Developments in Employment
- Share this
- Link this
- Digg this
Follow Reuters